Health Innovation Next Generation Payment & Pricing Models (HI-PRIX)

各种创新技术有可能彻底改变卫生保健的提供方式，这意味着政策工具箱将需要几种定价和支付模式，并根据具体情况进行设计和实施。虽然有一些新的定价和支付模式的例子，但缺乏适当的数据基础设施、法律障碍和不愿适应当前系统往往阻碍了它们的使用。因此，健康创新下一代定价模式（HI - PRIX）项目的总体目标是：i)绘制和制定新的定价和支付方案，这些方案可以跨技术类别、治疗领域、环境和医疗保健系统/地理区域使用，以及一套相关的原则，可以指导成功的调整和灵活的实施使用环境；㈡调查各种卫生创新承包方式对竞争力、创新、公平和可负担性的影响；Iii)通过在利益相关者群体之间就可负担性、创新和患者可及性之间的权衡进行有效对话，解决付款人、制造商、医疗保健专业人员和患者对不同定价模式的挑战和关切。HI-PRIX联盟由博科尼大学协调，涉及来自10个欧洲国家的18个合作伙伴，包括学术机构、公共当局、卫生保健提供者和独立研究组织。通过理论模型、定量模拟、定性研究工作和案例研究，这个为期三年的项目将围绕10个WPs构建，将产生新的证据，证明公共部门在研发中的作用，定价和报销决定中的间接医疗和环境成本，药品生命周期的定价动态，以及政策和激励对医疗保健系统的竞争力、创新性和公平性的影响。

The variety of innovative technologies with the potential to revolutionize the delivery of health care means that the policy toolbox will need several pricing and payment models, adapted in their design and implementation according to the specific situation. Although there are examples of novel pricing and payment models, the lack of appropriate data infrastructure, legal barriers and unwillingness to adapt current systems often prevent their use. Therefore, the overall objectives of the Health Innovation Next Generation Pricing Models (HI – PRIX) project are: i) to map and formulate new pricing and payment schemes that can be used across technology classes, therapeutic areas, setting and healthcare systems/geographies together with a related set of principles that may guide successful adjustment and flexible implementation to the context of use; ii) to investigate the impact on competitiveness, innovation, equity and affordability of a pipeline of contracting modalities for health innovations; iii) to address the challenges and concerns of payers, manufacturers, healthcare professionals, and patients about different models of pricing by sustaining an effective dialogue across stakeholders’ groups about the trade-offs between affordability, innovation and patient access. Coordinated by Bocconi University, the HI-PRIX Consortium involves 18 partners from 10 European countries, including academic institutions, public authorities, healthcare providers, and independent research organizations. Through theoretical models, quantitative simulation, qualitative research work and case-studies, this three-year project structured around 10 WPs, will generate new evidence on the role of public sector in R&D and indirect medical and environmental costs in pricing and reimbursement determinations, on the pricing dynamics over pharmaceutical products’ lifecycle, on the impact of policies and incentives on the competitiveness, innovativeness and equity in the healthcare system.